Home » Features » Companies » GVK


GVK is a leading Indian conglomerate with a presence across energy, resources, airports, transportation, hospitality and life sciences sectors. GVK set up India's first independent power plant and has around 6,000 MW of projects under generation, construction and development.

It is the first company in India to develop a six-lane road project under a PPP model and has around 3,000 lane km expressway projects under operation and construction. As one of India's largest private sector airport operators, GVK handles passenger traffic of 44 mpa through India's first brownfield airport under a PPP model - Chhatrapati Shivaji International Airport in Mumbai and Bengaluru International Airport, Bangalore, and will develop two airports in Indonesia. Having already invested over USD 3.3 billion, GVK has projects worth over another USD 6.6 billion in the pipeline in India.

Board of Directors

  • Dr. GVK Reddy - Founder, Chairman and Managing Director
  • GV Sanjay Reddy - Vice Chairman
  • Mrs. G Indira Krishna Reddy - Director
  • Mr. Krishna Ram Bhupal - Director
  • Dr. A Ramakrishna - Independent Director
  • Mr. K N Shenoy - Independent Director
  • Dr. Abid Hussain - Independent Director
  • Mr. P Abraham - Independent Director
  • Mr. CH G Krishna Murthy - Independent Director
  • Mr. S Balasubramanian - Independent Director
  • Mr. A Issac George - Director
  • Mrs. Ranjana Kumar - Independent Director

GVK in News

Frost & Sullivan Recognizes Innovative Strategies and Stellar Performance at its 7th Annual India Healthcare Excellence Awards 2015
Business Wire IndiaOver the years, Frost & Sullivan’s Healthcare Practice has recognized distinguished companies and individuals for their significant achievements and seamless contribution to the country’s healthcare industry

Kempegowda International Airport, Bengaluru (KIAB) Starts Trials for Introducing e-Gate System in India
Business Wire IndiaAs part of its ongoing effort to offer passengers a seamless travel experience, Bangalore International Airport Limited (BIAL) announced the introduction of automated E-Gates at KIAB that has been implemented on a trial basis at the Domestic pre-embarkation security check areas

Dermalogica Kick-starts 'Face Map Our Nation' Campaign

Excellence In Airport Community Honoured at the KIAB Pinnacle Awards 2015
Business Wire IndiaKempegowda International Airport, Bengaluru (KIAB) celebrated seven successful years of airport operation with the second edition of the Pinnacle Awards – a platform created to recognize excellence and collaboration within the airport community. The award ceremony was presided over by Mr

South India's Busiest Airport Selects SITA For Passenger Processing
Business Wire IndiaSouth India’s busiest airport, Kempegowda International Airport, Bengaluru (KIAB) which serves India’s “Silicon Valley” tech hub, will use passenger processing technology from air transport IT specialist, SITA, to help manage its more than 15 million annual passengers

Kempegowda International Airport, Bengaluru Clocks in 15 Million Passengers in 2014-15
Business Wire IndiaBangalore International Airport Limited (BIAL) announced that the Kempegowda International Airport, Bengaluru (KIAB) welcomed its 15 millionth passenger on late Sunday evening, March 22, 2015 marking the airport’s graduation to the mid-sized airport category (15 to 25 million passenger airports) classification within seven years of initiating operations

CSIA Inaugurates ‘GVK Lounge’ for First and Business Class Travellers at T2
‘GVK Lounge’ is the first ever Luxury Lounge at any airport in the world, common for all Airlines Spread across 30,000 sq. ft

GVK BIO Signs Definitive Agreement to Acquire Vanta Bioscience
Asia’s leading Discovery Research and Development organization, GVK BIO, announced the signing of a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP toxicology and safety assessment contract research organization operating out of Chennai, India. Complying with OECD GLP, ISO, USFDA GLP (21 CFR Part 58 rev

Mumbai International Airport Bags the Prestigious Golden Peacock Award 2014 for Sustainability
GVK Mumbai International Airport Private Limited (MIAL) has bagged the prestigious ‘Golden Peacock Award for Sustainability’ for the Chhatrapati Shivaji International Airport (CSIA). The award was presented at a specially organized “Golden Peacock Awards Ceremony”, on Wednesday, October 29 2014 at House of Lords- UK Parliament, Westminster in London

GVK BIO Announces Successful Completion of Drug Repurposing Efforts to Identify Novel Indications
GVK Biosciences (GVK BIO) – Asia’s leading integrated Discovery Research and Development organization today announced the successful completion of in-silico based alternative indications of shelved compounds for Takeda Pharmaceutical Company Limited using GVK BIO’s proprietary Drug Repurposing Platform

GVK MIAL Awarded Five Star Rating For Occupational Health and Safety Audit by BSC
Mumbai International Airport Private Limited (MIAL) has been graded with a Five Star rating by the prestigious British Safety Council (BSC), which is the highest grading awarded by BSC in its Occupational Health & Safety (OH&S) Management System Audits

GVK MIAL Releases Sustainability Report 2014
Building upon its commitment to sustainability, GVK Mumbai International Airport Private Limited (MIAL) today released its second annual Sustainability Report - “The Sustainability Report 2014” highlighting the achievements of GVK MIAL

Mumbai Passengers Express Interest in Mobile Travel Service
Passengers at Chhatrapati Shivaji International Airport in Mumbai have expressed strong interest in accessing and purchasing travel services using their mobiles, according to a recent global survey from SITA. However, first generation mobile travel services are not yet appealing enough for passengers to use them regularly, reports the SITA/Air Transport World Passenger IT Trends Survey

GVK BIO and Aragen Bioscience Sign Definitive Agreement to Acquire Aragen Bioscience, Inc.
The acquisition of Aragen Bioscience provides GVK BIO with world-class expertise in large molecule R&D services and a unique and extensive set of high-content biological services

CH2M HILL Congratulates GVK on the Inauguration of Terminal 2 at the Chhatrapati Shivaji International Airport
CH2M HILL, a global full-service consulting, design, construction, and operations firm, congratulates GVK's Mumbai International Pvt Ltd. (MIAL) on the inauguration of the industry-leading and state-of-the-art Terminal 2 (T2) at Chhatrapati Shivaji International Airport.  

Andhra Pradesh News on March 14, 2014
Andhra Pradesh News and Headlines on March 14, 2014

GVK BIO and US FDA Announce Drug Repositioning Collaboration - License to GVK BIO SAR Database GOSTAR
GVK Biosciences (GVK BIO) today announced that it has licensed its popular SAR, PK and Toxicity Database (GOSTAR) to the US Food and Drug Administration (USFDA). The Material Transfer Agreement forms the basis of collaboration in Drug Repositioning, wherein the initial focus will be to identify alternative therapeutic indications of marketed compounds for neglected and orphan diseases

Drug Discovery Unit (DDU), University of Dundee Licenses GVK BIO Online SAR Database (GOSTAR)
GVK Biosciences (GVK BIO) today announced that it has licensed its Online SAR Database - GOSTAR to the Drug Discovery Unit (DDU) at the University of Dundee. GOSTAR, a manually curated database, has been developed over the span of a decade by a team comprising of more than 200 curators

US FDA Extends License of the GVK BIO Biomarker Database
GVK Biosciences (GVK BIO) today announced that it is extending its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the US Food and Drug Administration (USFDA)

GVK BIO Enters into Research Collaboration with Endo Pharmaceuticals
GVK Biosciences (GVK BIO), Asia’s leading drug discovery research and development CRO announced today that it has entered into a collaboration agreement with U.S. based Endo Pharmaceuticals focused on discovering novel small molecules targeting an exciting protein

GVK Biosciences and Onconova Therapeutics Establish Novel Joint Development Partnership to Advance New Drugs for Cancer
GVK BIO, Asia’s leading Contract Research and Development organization and Onconova Therapeutics, a U.S. based biopharmaceutical company primarily focused on discovery and development of novel small molecules for Oncology, today announced that they have entered into a novel joint partnership to develop new drugs for Cancer. The joint partnership will be based in the U.S

GVK EMRI 108 in Madhya Pradesh attended 4 lakh emergencies
In the span of three and a half years GVK EMRI has attended more than 4 Lakh cases

Services of 108 ERS to all the Districts of MP till March 2013
GVK EMRI Madhya Pradesh to add 502 more ambulances by the end of March 2013

10th Edition of BioAsia 2013 – to be Held in Hyderabad from 28th to 30th January 2013
The 10th edition of much anticipated annual biotechnology and life sciences platform BioAsia will be held in Hyderabad from 28th to 30th of January. BioAsia 2013 will be held at the Hyderabad International Convention Centre (HICC), Hyderabad. Interested individuals, institutions, academia and companies can log on to to register themselves for participating in BioAsia 2013

GVK BIO Establishes the Largest Isotope Labeling Facility in India
GVK Biosciences (GVK BIO) , Asia’s leading Drug Discovery Research & Development organization, has received approvals from the Atomic Energy Regulatory Board (AERB), Government of India, to carry out 3H and 14C synthesis activities

All medical facilities available in 108 services says EMRI COO
108 service attends call within 25 minutes in cities and 15 minutes in rural areas

Chief Minister Kiran Kumar Reddy flags off advanced 108 services
752 ambulances under 108 services in the State

GVK receives Federal Environment Clearance for Alpha Coal project and Rail line in Australia
GVK's Alpha Coal Project Gains Federal Government Approval Under the Environment Protection and Biodiversity Conservation Act 1999 (EPBC)

Next-Generation DNA Sequencing Platforms Market to More Than Double to $3.2 Billion by 2017 cites in its newly published "DNA Sequencing and PCR Markets" report that the next-generation DNA sequencing platforms market will more than double, reaching $3.2 billion by 2017. For more information, visit:

Comment on this story